The current study shows that simvastatin inhibited the protein expression of phosphorylated p42/44, AKT and S6 in in ovarian cancer cell lines and orthotropic xenografts of serous ovarian cancer, suggesting simvastatin reduced the activity MAPK and AKT/mTOR pathways in ovarian cancer. The gene discussed is AKT1; the disease is ovarian serous adenocarcinoma.